Evotec

Carrick Therapeutics Closes Series C Financing

Retrieved on: 
Thursday, December 1, 2022

DUBLIN, Ireland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced it has raised $25 million in a Series C financing. The financing round was supported by existing investors, including ARCH Venture Partners, Rosetta Capital, Lightstone Ventures, Google Ventures, Cambridge Innovation Capital, and Evotec. The Company intends to use the proceeds to fund ongoing and planned samuraciclib clinical trials, ongoing development of its CDK12/13 inhibitor / Cyclin-K glue-degrader, and for working capital and general corporate purposes.

Key Points: 
  • DUBLIN, Ireland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced it has raised $25 million in a Series C financing.
  • This financing will enable us to accelerate development of our CDK7 and CDK12/13 inhibitors to potentially bring new treatment approaches to patients battling cancer, said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.
  • Carrick has raised a total of $60 million from the Series C financing and Pfizer investment.
  • For more information about Carrick Therapeutics, please visit www.carricktherapeutics.com .

EQS-News: Evotec SE reports results for the first nine months 2022 and provides corporate update

Retrieved on: 
Friday, November 11, 2022

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the financial results and corporate updates for the first nine months 2022.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the financial results and corporate updates for the first nine months 2022.
  • intersegment revenues) up 23% to 526.7m (9M 2021: 429.8m); EVTInnovate revenues up 20% to 121.9m (9M2021: 101.9m), against a very high comparable basis.
  • Expansion of clinical and commercial drug substance manufacturing capacities through acquisition of Central Glass Germany, operating as Evotec Drug Substance (Germany) GmbH (Evotec DS).
  • The following table provides an overview of the financial performance in the first nine months of 2022 compared to the same period in 2021.

Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022

SEATTLE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the quarter and nine months ended September 30, 2022.

Key Points: 
  • SEATTLE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the quarter and nine months ended September 30, 2022.
  • During the third quarter of 2022, we continued advancing our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases.
  • Quarter and Nine Months Ended September 30, 2022 Financial Results
    Cash Position Cash, cash equivalents and marketable securities totaled $397.7 million at September 30, 2022, compared to $355.1 million at December 31, 2021.
  • Chinook assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

EQS-News: Evotec completes acquisition of Central Glass Germany

Retrieved on: 
Monday, November 7, 2022

AS EVOTEC DRUG SUBSTANCE (GERMANY) GMBH, THE ACQUISITION STRENGTHENS EVOTECS CLINICAL AND COMMERCIAL DRUG SUBSTANCE MANUFACTURING CAPACITY AND CAPABILITY ESPECIALLY FOR RARE DISEASES AND PRECISION THERAPEUTICS

Key Points: 
  • AS EVOTEC DRUG SUBSTANCE (GERMANY) GMBH, THE ACQUISITION STRENGTHENS EVOTECS CLINICAL AND COMMERCIAL DRUG SUBSTANCE MANUFACTURING CAPACITY AND CAPABILITY ESPECIALLY FOR RARE DISEASES AND PRECISION THERAPEUTICS
    Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in August 2022, has been completed.
  • As Evotec Drug Substance (Germany) GmbH (Evotec DS), the strategic transaction strengthens Evotecs clinical and commercial manufacturing capacity and capability for small molecule therapeutics.
  • Located in Halle/Westphalia, Germany, Evotec DS comprises a team of approximately 60 highly skilled chemical manufacturing experts and a fully operational EU cGMP certified facility.
  • Evotec DS provides a high-quality, European-based solution to Evotecs partners for the development and commercialisation of drug substances, especially for rare diseases and precision therapeutics.

EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day

Retrieved on: 
Thursday, November 3, 2022

The programme entitled: Paradigm shift in Biologics will take place at its J.POD Redmond, WA (US) facility.

Key Points: 
  • The programme entitled: Paradigm shift in Biologics will take place at its J.POD Redmond, WA (US) facility.
  • Just Evotec Biologics technology platforms unlock the potential of biologics for diseases affecting large and small patient populations and enables affordable commercialisation strategies for novel effective antibody combination therapies.
  • Just Evotec Biologics today announced that it has been selected for a second award under the Accelerated Antibodies Program.
  • Evotec hosts its Capital Markets Day on 02 November 2022, starting at 9.00 am PDT (12.00 pm EDT, 5.00 pm CET) with a site tour.

EQS-News: Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions

Retrieved on: 
Friday, October 28, 2022

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the launch of Extend, a translational BRIDGE partnership in cooperation with CDP Venture Capital Sgr, a strategic pillar to Italy's economic growth and innovation, and Angelini Ventures, the Corporate Venture Capital arm of the multi-business industrial group Angelini Industries.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the launch of Extend, a translational BRIDGE partnership in cooperation with CDP Venture Capital Sgr, a strategic pillar to Italy's economic growth and innovation, and Angelini Ventures, the Corporate Venture Capital arm of the multi-business industrial group Angelini Industries.
  • Extend is a joint venture between Evotec, CDP Venture Capital and Angelini Ventures to develop translational drug discovery partnerships with highly renowned universities and research centres in Italy.
  • Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: We are excited to launch Extend together with our partners at CDP Venture Capital and Angelini Ventures.
  • Extend brings together leading academic institutions from Italy to accelerate their most promising assets towards commercialisation.

EQS-News: Evotec enters partnership with Hannover Medical School to create molecular patient database in autoimmune diseases

Retrieved on: 
Friday, October 28, 2022

Together with supplementary pseudonymised patient data, these PanOmics data will feed into Evotecs proprietary translational molecular patient data platform E.MPD, which serves as the central data repository for molecular patient data.

Key Points: 
  • Together with supplementary pseudonymised patient data, these PanOmics data will feed into Evotecs proprietary translational molecular patient data platform E.MPD, which serves as the central data repository for molecular patient data.
  • Evotec has the exclusive right to exploit the data commercially with its unique capabilities in the field of data-driven precision medicine.
  • Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: We are excited to enter this partnership with MHH and expand Evotecs E.MPD database into autoimmune diseases.
  • E.MPD, Evotecs translational molecular patient database, is one of the largest and highest quality molecular databases globally.

EQS-News: Evotec and TIAP expand LAB150 BRIDGE partnership to include Amgen

Retrieved on: 
Saturday, October 22, 2022

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Toronto Innovation Acceleration Partners (TIAP) today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Toronto Innovation Acceleration Partners (TIAP) today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner.
  • LAB150 was created by Evotec and TIAP in 2017 to accelerate Torontos academic research into market-ready products.
  • Amgen will provide financial support for chosen LAB150 projects along with significant mentorship from their drug discovery and development teams.
  • Together with Evotec, we look forward to collaborating with Amgen to bring enhanced expertise and capital to LAB150 to enable life science company creation, said Parimal Nathwani, President and CEO of TIAP.

EQS-News: Evotec launches PanOmics data analysis platform PanHunter at Bio-IT World

Retrieved on: 
Saturday, October 22, 2022

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the launch of the first commercial version of its PanOmics data analysis platform PanHunter at Bio-IT World (18-19 October in Berlin, Germany).

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the launch of the first commercial version of its PanOmics data analysis platform PanHunter at Bio-IT World (18-19 October in Berlin, Germany).
  • PanHunter is Evotecs PanOmics data access and analytics platform and was developed and used successfully internally and in industry-shaping drug discovery partnerships over many years.
  • The amount of available PanOmics data is growing at exponential rates in the public domain and in the pharmaceutical industry.
  • PanHunter is unique in its ability to integrate the analysis of PanOmics data, designed as an easy-to-use yet fully comprehensive PanOmics data analysis platform.

TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen

Retrieved on: 
Monday, October 17, 2022

Toronto Innovation Acceleration Partners (TIAP) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner.

Key Points: 
  • Toronto Innovation Acceleration Partners (TIAP) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner.
  • LAB150 was created by TIAP and Evotec in 2017 to accelerate Torontos academic research into market-ready products.
  • Amgen will provide financial support for chosen LAB150 projects along with significant mentorship from their drug discovery and development teams.
  • Together with Evotec, we look forward to collaborating with Amgen to bring enhanced expertise and capital to LAB150 to enable life science company creation, said Parimal Nathwani, President and CEO of TIAP.